메뉴 건너뛰기




Volumn 8, Issue 9, 2012, Pages 1227-1236

Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases

Author keywords

A humanized anti interleukin 6 receptor antibody; Autoimmune; Inflammation; Interleukin 6; Tocilizumab

Indexed keywords

INTERLEUKIN 6; MONOCLONAL ANTIBODY; TOCILIZUMAB;

EID: 84869755800     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4666     Document Type: Review
Times cited : (205)

References (168)
  • 1
    • 0022499547 scopus 로고
    • Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
    • Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324: 73-76.
    • (1986) Nature , vol.324 , pp. 73-76
    • Hirano, T.1    Yasukawa, K.2    Harada, H.3
  • 2
    • 0024360388 scopus 로고
    • The biology of interleukin-6
    • Kishimoto T. The biology of interleukin-6. Blood. 1989; 74: 1-10.
    • (1989) Blood , vol.74 , pp. 1-10
    • Kishimoto, T.1
  • 3
    • 17644368573 scopus 로고    scopus 로고
    • Interleukin-6: From basic science to medicine-40 years in immunology
    • Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005; 23: 1-21.
    • (2005) Annu Rev Immunol , vol.23 , pp. 1-21
    • Kishimoto, T.1
  • 6
    • 0037066427 scopus 로고    scopus 로고
    • The danger model: A renewed sense of self
    • Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296: 301-305.
    • (2002) Science , vol.296 , pp. 301-305
    • Matzinger, P.1
  • 7
    • 0025190892 scopus 로고
    • Interleukin-6 and the acute phase response
    • Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265: 621-636.
    • (1990) Biochem J , vol.265 , pp. 621-636
    • Heinrich, P.C.1    Castell, J.V.2    Andus, T.3
  • 8
    • 0034234716 scopus 로고    scopus 로고
    • Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleu-kin 6 dependent
    • Siewert E, Bort R, Kluge R, et al. Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleu-kin 6 dependent. Hepatology. 2000; 32: 49-55.
    • (2000) Hepatology , vol.32 , pp. 49-55
    • Siewert, E.1    Bort, R.2    Kluge, R.3
  • 9
    • 49149095841 scopus 로고    scopus 로고
    • Transcriptional complex formation of c-Fos, STAT3, and Hepatocyte NF-1alpha is essential for cyto-kine-driven C-reactive protein gene expression
    • Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and Hepatocyte NF-1alpha is essential for cyto-kine-driven C-reactive protein gene expression. J Immunol. 2008; 180: 3492-3501.
    • (2008) J Immunol , vol.180 , pp. 3492-3501
    • Nishikawa, T.1    Hagihara, K.2    Serada, S.3
  • 10
    • 58149154996 scopus 로고    scopus 로고
    • Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocili-zumab, in patients with rheumatoid arthritis and Castleman disease
    • Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocili-zumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112: 3959-3964.
    • (2008) Blood , vol.112 , pp. 3959-3964
    • Nishimoto, N.1    Terao, K.2    Mima, T.3
  • 11
    • 2342510407 scopus 로고    scopus 로고
    • IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
    • Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276.
    • (2004) J Clin Invest , vol.113 , pp. 1271-1276
    • Nemeth, E.1    Rivera, S.2    Gabayan, V.3
  • 12
    • 27744561904 scopus 로고    scopus 로고
    • Clinical aspects of systemic amyloid diseases
    • Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005; 1753: 11-22.
    • (2005) Biochim Biophys Acta , vol.1753 , pp. 11-22
    • Obici, L.1    Perfetti, V.2    Palladini, G.3
  • 14
    • 77954096689 scopus 로고    scopus 로고
    • IL-6: Regulator of Treg/Th17 balance
    • Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010; 40: 1830-1835.
    • (2010) Eur J Immunol , vol.40 , pp. 1830-1835
    • Kimura, A.1    Kishimoto, T.2
  • 15
    • 80053262406 scopus 로고    scopus 로고
    • Human FoxP3+ regulatory T cells in systemic autoimmune diseases
    • Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011; 10: 744-755.
    • (2011) Autoimmun Rev , vol.10 , pp. 744-755
    • Miyara, M.1    Gorochov, G.2    Ehrenstein, M.3
  • 16
    • 0023803252 scopus 로고
    • IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells
    • Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988; 141: 1543-1549.
    • (1988) J Immunol , vol.141 , pp. 1543-1549
    • Okada, M.1    Kitahara, M.2    Kishimoto, S.3
  • 17
    • 0024446495 scopus 로고
    • Interleukin-6 is a potent thrombopoietic factor in vivo in mice
    • Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989; 74: 1241-1244.
    • (1989) Blood , vol.74 , pp. 1241-1244
    • Ishibashi, T.1    Kimura, H.2    Shikama, Y.3
  • 18
    • 13344250490 scopus 로고    scopus 로고
    • Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
    • Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996; 11: 88-95.
    • (1996) J Bone Miner Res , vol.11 , pp. 88-95
    • Kotake, S.1    Sato, K.2    Kim, K.J.3
  • 19
    • 0038798085 scopus 로고    scopus 로고
    • Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
    • Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003; 48: 1521-1529.
    • (2003) Arthritis Rheum , vol.48 , pp. 1521-1529
    • Nakahara, H.1    Song, J.2    Sugimoto, M.3
  • 20
    • 0343019918 scopus 로고
    • Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes
    • Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA. 1989; 86: 6367-6371.
    • (1989) Proc Natl Acad Sci USA , vol.86 , pp. 6367-6371
    • Grossman, R.M.1    Krueger, J.2    Yourish, D.3
  • 21
    • 0025989368 scopus 로고
    • Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6
    • Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991; 97: 686-692.
    • (1991) J Invest Dermatol , vol.97 , pp. 686-692
    • Duncan, M.R.1    Berman, B.2
  • 22
    • 0023849455 scopus 로고
    • Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
    • Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332: 83-85.
    • (1988) Nature , vol.332 , pp. 83-85
    • Kawano, M.1    Hirano, T.2    Matsuda, T.3
  • 23
    • 0345317621 scopus 로고
    • IgG1 plasmacytosis in interleu-kin 6 transgenic mice
    • Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleu-kin 6 transgenic mice. Proc Natl Acad Sci USA. 1989; 86: 7547-7551.
    • (1989) Proc Natl Acad Sci USA , vol.86 , pp. 7547-7551
    • Suematsu, S.1    Matsuda, T.2    Aozasa, K.3
  • 24
    • 0024805715 scopus 로고
    • Involvement of IL-6 in mesangial proliferative glomerulonephritis
    • Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989; 143: 3949-3955.
    • (1989) J Immunol , vol.143 , pp. 3949-3955
    • Horii, Y.1    Muraguchi, A.2    Iwano, M.3
  • 25
    • 0023685762 scopus 로고
    • Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor
    • Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241: 825-828.
    • (1988) Science , vol.241 , pp. 825-828
    • Yamasaki, K.1    Taga, T.2    Hirata, Y.3
  • 26
    • 0026485304 scopus 로고
    • Interleukin-6 and its receptor: A paradigm for cytokines
    • Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992; 258: 593-597.
    • (1992) Science , vol.258 , pp. 593-597
    • Kishimoto, T.1    Akira, S.2    Taga, T.3
  • 27
    • 0025630163 scopus 로고
    • Molecular cloning and expression of an IL-6 signal transducer, gp130
    • Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990; 63: 1149-1157.
    • (1990) Cell , vol.63 , pp. 1149-1157
    • Hibi, M.1    Murakami, M.2    Saito, M.3
  • 28
    • 0029084805 scopus 로고
    • Interleukin-6 family of cytokines and gp130
    • Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995; 86: 1243-1254.
    • (1995) Blood , vol.86 , pp. 1243-1254
    • Kishimoto, T.1    Akira, S.2    Narazaki, M.3
  • 29
    • 0030890718 scopus 로고    scopus 로고
    • Gp130 and the interleukin-6 family of cytokines
    • Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997; 15: 797-819.
    • (1997) Annu Rev Immunol , vol.15 , pp. 797-819
    • Taga, T.1    Kishimoto, T.2
  • 30
    • 0027199126 scopus 로고
    • IL-6-induced homodimeriza-tion of gp130 and associated activation of a tyrosine kinase
    • Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimeriza-tion of gp130 and associated activation of a tyrosine kinase. Science. 1993; 260: 1808-1810.
    • (1993) Science , vol.260 , pp. 1808-1810
    • Murakami, M.1    Hibi, M.2    Nakagawa, N.3
  • 31
    • 0038609651 scopus 로고    scopus 로고
    • Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex
    • Boulanger MJ, Chow DC, Brevnova EE, et al. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300: 2101-2104.
    • (2003) Science , vol.300 , pp. 2101-2104
    • Boulanger, M.J.1    Chow, D.C.2    Brevnova, E.E.3
  • 32
    • 80052358980 scopus 로고    scopus 로고
    • Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
    • Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121: 3375-3383.
    • (2011) J Clin Invest , vol.121 , pp. 3375-3383
    • Jones, S.A.1    Scheller, J.2    Rose-John, S.3
  • 33
    • 0027421831 scopus 로고
    • Interleukin-6 in biology and medicine
    • Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78.
    • (1993) Adv Immunol , vol.54 , pp. 1-78
    • Akira, S.1    Taga, T.2    Kishimoto, T.3
  • 34
    • 0035892118 scopus 로고    scopus 로고
    • Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus
    • Aoki Y, Narazaki M, Kishimoto T, et al. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus. Blood. 2001; 98: 3042-3049.
    • (2001) Blood , vol.98 , pp. 3042-3049
    • Aoki, Y.1    Narazaki, M.2    Kishimoto, T.3
  • 35
    • 0025183151 scopus 로고
    • Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice
    • Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990; 86: 592-599.
    • (1990) J Clin Invest , vol.86 , pp. 592-599
    • Brandt, S.J.1    Bodine, D.M.2    Dunbar, C.E.3
  • 36
    • 84869830784 scopus 로고    scopus 로고
    • Immunotherapy of tocilizumab for rheumatoid arthritis
    • S6-S01
    • Tanaka T, Kishimoto T. Immunotherapy of tocilizumab for rheumatoid arthritis. J Clin Cell Immunol. 2011;: S6-S01.
    • (2011) J Clin Cell Immunol
    • Tanaka, T.1    Kishimoto, T.2
  • 37
    • 0032536542 scopus 로고    scopus 로고
    • Interleukin 6 is required for the development of collagen-induced arthritis
    • Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998; 187: 461-468.
    • (1998) J Exp Med , vol.187 , pp. 461-468
    • Alonzi, T.1    Fattori, E.2    Lazzaro, D.3
  • 38
    • 0032429668 scopus 로고    scopus 로고
    • Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
    • Takagi N, Mihara M, Moriya Y, et al. Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998; 41: 2117-2121.
    • (1998) Arthritis Rheum , vol.41 , pp. 2117-2121
    • Takagi, N.1    Mihara, M.2    Moriya, Y.3
  • 39
    • 13144259627 scopus 로고    scopus 로고
    • Interleukin 6 plays a key role in the development of antigen-induced arthritis
    • Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 1998; 95: 8222-8226.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 8222-8226
    • Ohshima, S.1    Saeki, Y.2    Mima, T.3
  • 40
    • 0033503152 scopus 로고    scopus 로고
    • Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice
    • Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999; 42: 1635-1643.
    • (1999) Arthritis Rheum , vol.42 , pp. 1635-1643
    • Sasai, M.1    Saeki, Y.2    Ohshima, S.3
  • 41
    • 0035990220 scopus 로고    scopus 로고
    • Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: Evidence that interleukin 6 is essential for induction of AIA
    • Kobayashi H, Ohshima S, Nishioka K, et al. Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA. J Rheumatol. 2002; 29: 1176-1182.
    • (2002) J Rheumatol , vol.29 , pp. 1176-1182
    • Kobayashi, H.1    Ohshima, S.2    Nishioka, K.3
  • 42
    • 31044449633 scopus 로고    scopus 로고
    • Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis
    • Wong PK, Quinn JM, Sims NA, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006; 54: 158-168.
    • (2006) Arthritis Rheum , vol.54 , pp. 158-168
    • Wong, P.K.1    Quinn, J.M.2    Sims, N.A.3
  • 43
    • 4344590199 scopus 로고    scopus 로고
    • Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice
    • Hata H, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004; 114: 582-588.
    • (2004) J Clin Invest , vol.114 , pp. 582-588
    • Hata, H.1    Sakaguchi, N.2    Yoshitomi, H.3
  • 44
    • 33846456970 scopus 로고    scopus 로고
    • T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis
    • Hirota K, Hashimoto M, Yoshitomi H, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007; 204: 41-47.
    • (2007) J Exp Med , vol.204 , pp. 41-47
    • Hirota, K.1    Hashimoto, M.2    Yoshitomi, H.3
  • 45
    • 0029148912 scopus 로고
    • Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans
    • Iwakura Y, Saijo S, Kioka Y, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol. 1995; 155: 1588-1598.
    • (1995) J Immunol , vol.155 , pp. 1588-1598
    • Iwakura, Y.1    Saijo, S.2    Kioka, Y.3
  • 46
    • 0037037586 scopus 로고    scopus 로고
    • A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis
    • Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002; 196: 979-990.
    • (2002) J Exp Med , vol.196 , pp. 979-990
    • Atsumi, T.1    Ishihara, K.2    Kamimura, D.3
  • 47
    • 57349083145 scopus 로고    scopus 로고
    • Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses
    • Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008; 58: 3710-3719.
    • (2008) Arthritis Rheum , vol.58 , pp. 3710-3719
    • Fujimoto, M.1    Serada, S.2    Mihara, M.3
  • 48
    • 40549102753 scopus 로고    scopus 로고
    • Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
    • Iwanami K, Matsumoto I, Tanaka-Watanabe Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008; 58: 754-763.
    • (2008) Arthritis Rheum , vol.58 , pp. 754-763
    • Iwanami, K.1    Matsumoto, I.2    Tanaka-Watanabe, Y.3
  • 49
    • 0031861643 scopus 로고    scopus 로고
    • IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
    • Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998; 112: 397-402.
    • (1998) Clin Exp Immunol , vol.112 , pp. 397-402
    • Mihara, M.1    Takagi, N.2    Takeda, Y.3
  • 50
    • 33750011260 scopus 로고    scopus 로고
    • Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus
    • Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006; 119: 296-305.
    • (2006) Immunology , vol.119 , pp. 296-305
    • Liang, B.1    Gardner, D.B.2    Griswold, D.E.3
  • 51
    • 73949099325 scopus 로고    scopus 로고
    • Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling
    • Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA. 2009; 106: 20423-20428.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 20423-20428
    • Pflegerl, P.1    Vesely, P.2    Hantusch, B.3
  • 52
    • 83455230778 scopus 로고    scopus 로고
    • Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma
    • Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012; 80: 165-176.
    • (2012) Am J Pathol , vol.80 , pp. 165-176
    • Kitaba, S.1    Murota, H.2    Terao, M.3
  • 53
    • 80155206307 scopus 로고    scopus 로고
    • Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling
    • Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011; 63: 3575-3585.
    • (2011) Arthritis Rheum , vol.63 , pp. 3575-3585
    • Yoshizaki, A.1    Yanaba, K.2    Ogawa, A.3
  • 54
    • 68049088818 scopus 로고    scopus 로고
    • Therapeutic effects of inter-leukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A
    • Okiyama N, Sugihara T, Iwakura Y, et al. Therapeutic effects of inter-leukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009; 60: 2505-2512.
    • (2009) Arthritis Rheum , vol.60 , pp. 2505-2512
    • Okiyama, N.1    Sugihara, T.2    Iwakura, Y.3
  • 55
    • 77954952358 scopus 로고    scopus 로고
    • Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses
    • Hohki S, Ohguro N, Haruta H, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010; 91: 162-170.
    • (2010) Exp Eye Res , vol.91 , pp. 162-170
    • Hohki, S.1    Ohguro, N.2    Haruta, H.3
  • 56
    • 79961008060 scopus 로고    scopus 로고
    • Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis
    • Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011; 52: 3264-3271.
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 3264-3271
    • Haruta, H.1    Ohguro, N.2    Fujimoto, M.3
  • 57
    • 48249148236 scopus 로고    scopus 로고
    • IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis
    • Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008; 105: 9041-9046.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 9041-9046
    • Serada, S.1    Fujimoto, M.2    Mihara, M.3
  • 58
    • 81755184476 scopus 로고    scopus 로고
    • Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
    • Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS lett. 2011; 585: 3699-3709.
    • (2011) FEBS Lett , vol.585 , pp. 3699-3709
    • Tanaka, T.1    Narazaki, M.2    Kishimoto, T.3
  • 60
    • 2642558925 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multi-center, double-blind, placebo-controlled trial
    • Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50: 1761-1769.
    • (2004) Arthritis Rheum , vol.50 , pp. 1761-1769
    • Nishimoto, N.1    Yoshizaki, K.2    Miyasaka, N.3
  • 61
    • 33749363027 scopus 로고    scopus 로고
    • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • CHARISMA Study Group
    • Maini RN, Taylor PC, Szechinski J, et al; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
    • (2006) Arthritis Rheum , vol.54 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3
  • 62
    • 70349402169 scopus 로고    scopus 로고
    • Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study
    • Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009; 68: 1580-1584.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1580-1584
    • Nishimoto, N.1    Miyasaka, N.2    Yamamoto, K.3
  • 63
    • 73449118587 scopus 로고    scopus 로고
    • Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
    • Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96.
    • (2010) Ann Rheum Dis , vol.69 , pp. 88-96
    • Jones, G.1    Sebba, A.2    Gu, J.3
  • 64
    • 40749114497 scopus 로고    scopus 로고
    • OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial
    • Smolen JS, Beaulieu A, Rubbert-Roth A, et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008; 371: 987-997.
    • (2008) Lancet , vol.371 , pp. 987-997
    • Smolen, J.S.1    Beaulieu, A.2    Rubbert-Roth, A.3
  • 65
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The TCZ in combination with traditional disease-modifying antirheumatic drug therapy study
    • Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58: 2968-2980.
    • (2008) Arthritis Rheum , vol.58 , pp. 2968-2980
    • Genovese, M.C.1    McKay, J.D.2    Nasonov, E.L.3
  • 66
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: Results from a 24-week multicentre randomized placebo controlled trial
    • Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann Rheum Dis. 2008; 67: 1516-1523.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3
  • 67
    • 31544451391 scopus 로고    scopus 로고
    • Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
    • Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005; 7: R1281-288.
    • (2005) Arthritis Res Ther , vol.7
    • Woo, P.1    Wilkinson, N.2    Prieur, A.M.3
  • 68
    • 20144362101 scopus 로고    scopus 로고
    • Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis
    • Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818-825.
    • (2005) Arthritis Rheum , vol.52 , pp. 818-825
    • Yokota, S.1    Miyamae, T.2    Imagawa, T.3
  • 69
    • 40749152243 scopus 로고    scopus 로고
    • Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomized, double-blind, placebo-controlled, withdrawal phase III trial
    • Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 1006-1998.
    • (2008) Lancet , vol.371 , pp. 1006-1998
    • Yokota, S.1    Imagawa, T.2    Mori, M.3
  • 70
    • 84869843659 scopus 로고    scopus 로고
    • Tocilizumab in patients with systemic juvenile idiopathic arthritis: Efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial
    • De Benedetti F, Brunner H, Ruperto N, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum. 2010; 62(Suppl 10): 1434.
    • (2010) Arthritis Rheum , vol.62 , Issue.SUPPL. 10 , pp. 1434
    • de Benedetti, F.1    Brunner, H.2    Ruperto, N.3
  • 71
    • 84871090569 scopus 로고    scopus 로고
    • Efficacy and safety of tocil-izumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): Tender 52-week data
    • De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocil-izumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediat Rheumatol. 2011; 9(Suppl 1): 164.
    • (2011) Pediat Rheumatol , vol.9 , Issue.SUPPL. 1 , pp. 164
    • de Benedetti, F.1    Brunner, H.2    Ruperto, N.3
  • 72
    • 0033959608 scopus 로고    scopus 로고
    • Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
    • Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000; 95: 56-61.
    • (2000) Blood , vol.95 , pp. 56-61
    • Nishimoto, N.1    Sasai, M.2    Shima, Y.3
  • 73
    • 27144488346 scopus 로고    scopus 로고
    • Humanized an-ti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
    • Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized an-ti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106: 2627-2632.
    • (2005) Blood , vol.106 , pp. 2627-2632
    • Nishimoto, N.1    Kanakura, Y.2    Aozasa, K.3
  • 74
    • 75749113331 scopus 로고    scopus 로고
    • Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
    • Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62: 542-552.
    • (2010) Arthritis Rheum , vol.62 , pp. 542-552
    • Illei, G.G.1    Shirota, Y.2    Yarboro, C.H.3
  • 76
    • 84859757911 scopus 로고    scopus 로고
    • Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urti-carial vasculitis
    • Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urti-carial vasculitis. J Clin Rheumatol. 2012; 18: 92-95.
    • (2012) J Clin Rheumatol , vol.18 , pp. 92-95
    • Makol, A.1    Gibson, L.E.2    Michet, C.J.3
  • 77
    • 78049421175 scopus 로고    scopus 로고
    • The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
    • Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010; 49: 2408-2412.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 2408-2412
    • Shima, Y.1    Kuwahara, Y.2    Murota, H.3
  • 78
    • 79959478448 scopus 로고    scopus 로고
    • Therapeutic effect of tocili-zumab on two patients with polymyositis
    • Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocili-zumab on two patients with polymyositis. Rheumatology (Oxford). 2011; 50: 1344-1346.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 1344-1346
    • Narazaki, M.1    Hagihara, K.2    Shima, Y.3
  • 79
    • 79955751346 scopus 로고    scopus 로고
    • Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
    • Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011; 141: w13156.
    • (2011) Swiss Med Wkly , vol.141
    • Seitz, M.1    Reichenbach, S.2    Bonel, H.M.3
  • 80
    • 80052495918 scopus 로고    scopus 로고
    • Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis
    • Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011; 70: 1874-1875.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1874-1875
    • Beyer, C.1    Axmann, R.2    Sahinbegovic, E.3
  • 81
    • 80052318064 scopus 로고    scopus 로고
    • Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis
    • Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011; 38: 2080-2081.
    • (2011) J Rheumatol , vol.38 , pp. 2080-2081
    • Sciascia, S.1    Rossi, D.2    Roccatello, D.3
  • 82
    • 84855162831 scopus 로고    scopus 로고
    • Tocilizumab: A novel therapy for patients with large-vessel vasculitis
    • Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (0xford). 2012; 51: 151-156.
    • (2012) Rheumatology (0xford) , vol.51 , pp. 151-156
    • Salvarani, C.1    Magnani, L.2    Catanoso, M.3
  • 83
    • 84860566126 scopus 로고    scopus 로고
    • Efficacy of tocilizumab in refractory giant cell arteritis
    • Vinit J, Bielefeld P, Muller G, et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine. 2012; 79: 317-318.
    • (2012) Joint Bone Spine , vol.79 , pp. 317-318
    • Vinit, J.1    Bielefeld, P.2    Muller, G.3
  • 85
    • 42449088420 scopus 로고    scopus 로고
    • Successful treatment of a patient with Takayasu arteritis using a humanized an-ti-interleukin-6 receptor antibody
    • Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized an-ti-interleukin-6 receptor antibody. Arthritis Rheum. 2008; 58: 1197-200.
    • (2008) Arthritis Rheum , vol.58 , pp. 1197-1200
    • Nishimoto, N.1    Nakahara, H.2    Yoshio-Hoshino, N.3
  • 86
    • 84863756702 scopus 로고    scopus 로고
    • Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers
    • [Epub ahead of print]
    • Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol. 2012; [Epub ahead of print].
    • (2012) Clin Exp Rheumatol
    • Salvarani, C.1    Magnani, L.2    Catanoso, M.G.3
  • 87
    • 84863744973 scopus 로고    scopus 로고
    • One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab
    • [Epub ahead of print]
    • Bredemeier M, Rocha CM, Barbosa MV, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012; [Epub ahead of print].
    • (2012) Clin Exp Rheumatol
    • Bredemeier, M.1    Rocha, C.M.2    Barbosa, M.V.3
  • 88
    • 84857915035 scopus 로고    scopus 로고
    • Efficacy of tocil-izumab in rituximab-refractory cryoglobulinemia vasculitis
    • Cohen C, Mekinian A, Saidenberg-Kermanach N, et al. Efficacy of tocil-izumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis. 2012; 71: 628-629.
    • (2012) Ann Rheum Dis , vol.71 , pp. 628-629
    • Cohen, C.1    Mekinian, A.2    Saidenberg-Kermanach, N.3
  • 89
    • 80053159298 scopus 로고    scopus 로고
    • Complete remission of myelop-eroxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody
    • Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myelop-eroxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (0xford). 2011; 50: 1928-1930.
    • (2011) Rheumatology (0xford) , vol.50 , pp. 1928-1930
    • Sumida, K.1    Ubara, Y.2    Suwabe, T.3
  • 90
    • 79960393209 scopus 로고    scopus 로고
    • Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis
    • Sumida K, Ubara Y, Takemoto F, et al. Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol. 2011; 29(1 Suppl 64): S133.
    • (2011) Clin Exp Rheumatol , vol.29 , Issue.1 SUPPL. 64
    • Sumida, K.1    Ubara, Y.2    Takemoto, F.3
  • 91
    • 11144358366 scopus 로고    scopus 로고
    • A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
    • Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004; 126: 989-996.
    • (2004) Gastroenterology , vol.126 , pp. 989-996
    • Ito, H.1    Takazoe, M.2    Fukuda, Y.3
  • 92
    • 61349092994 scopus 로고    scopus 로고
    • Sustained response to tocili-zumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis
    • Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocili-zumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford). 2009; 48: 318-319.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 318-319
    • Kawai, M.1    Hagihara, K.2    Hirano, T.3
  • 93
    • 84860257586 scopus 로고    scopus 로고
    • Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing poly-chondritis complicated by aortitis
    • Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing poly-chondritis complicated by aortitis. Rheumatology (Oxford). 2012; 51: 952-953.
    • (2012) Rheumatology (Oxford) , vol.51 , pp. 952-953
    • Narshi, C.B.1    Allard, S.A.2
  • 94
    • 83255170953 scopus 로고    scopus 로고
    • Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocili-zumab
    • Nishida S, Kawasaki T, Kashiwagi H, et al. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocili-zumab. Mod Rheumatol. 2011; 21: 420-422.
    • (2011) Mod Rheumatol , vol.21 , pp. 420-422
    • Nishida, S.1    Kawasaki, T.2    Kashiwagi, H.3
  • 95
    • 79960206055 scopus 로고    scopus 로고
    • Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy
    • Yuzuriha A, Saitoh T, Koiso H, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 2011; 126: 147-150.
    • (2011) Acta Haematol , vol.126 , pp. 147-150
    • Yuzuriha, A.1    Saitoh, T.2    Koiso, H.3
  • 96
    • 84867115230 scopus 로고    scopus 로고
    • Tocil-izumab for treating refractory haemolytic anemia in a patient with systemic lupus erythematosus
    • [Epub ahead of print]
    • GarciaHernandez FJ, GonzalezLeon R, CastilloPalma MJ, et al. Tocil-izumab for treating refractory haemolytic anemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012; [Epub ahead of print].
    • (2012) Rheumatology (Oxford)
    • Garciahernandez, F.J.1    Gonzalezleon, R.2    Castillopalma, M.J.3
  • 97
    • 0036898472 scopus 로고    scopus 로고
    • Humanized monoclonal an-ti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease
    • Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal an-ti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002; 46: 3388-3389.
    • (2002) Arthritis Rheum , vol.46 , pp. 3388-3389
    • Iwamoto, M.1    Nara, H.2    Hirata, D.3
  • 98
    • 60149096148 scopus 로고    scopus 로고
    • A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years
    • Nakahara H, Mima T, Yoshino-Hoshino N, et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009; 19: 69-72.
    • (2009) Mod Rheumatol , vol.19 , pp. 69-72
    • Nakahara, H.1    Mima, T.2    Yoshino-Hoshino, N.3
  • 99
    • 58349119558 scopus 로고    scopus 로고
    • Tocilizumab for multirefractory adult-onset Still's disease
    • De Bandt M. Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis. 2009; 68: 153-154.
    • (2009) Ann Rheum Dis , vol.68 , pp. 153-154
    • de Bandt, M.1    Saint-Marcoux, B.2
  • 100
    • 61549119438 scopus 로고    scopus 로고
    • Glucocorticoid and cy-closporine refractory adult onset Still's disease successfully treated with tocilizumab
    • Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cy-closporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol. 2009; 28: 485-487.
    • (2009) Clin Rheumatol , vol.28 , pp. 485-487
    • Matsumoto, K.1    Nagashima, T.2    Takatori, S.3
  • 101
    • 79952461285 scopus 로고    scopus 로고
    • The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease
    • Cunha ML, Wagner J, Osawa A, et al. The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. Rheumatology (Oxford). 2010; 49: 1014-1016.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 1014-1016
    • Cunha, M.L.1    Wagner, J.2    Osawa, A.3
  • 102
    • 79952108981 scopus 로고    scopus 로고
    • Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab
    • Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010; 29: 1191-1194.
    • (2010) Clin Rheumatol , vol.29 , pp. 1191-1194
    • Sumida, K.1    Ubara, Y.2    Hoshino, J.3
  • 103
    • 77949512903 scopus 로고    scopus 로고
    • Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)
    • Yoshimura M, Makiyama J, Koga T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol. 2010; 28: 141-142.
    • (2010) Clin Exp Rheumatol , vol.28 , pp. 141-142
    • Yoshimura, M.1    Makiyama, J.2    Koga, T.3
  • 104
    • 78649326282 scopus 로고    scopus 로고
    • A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature
    • Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol. 2010; 29: 1465-1467.
    • (2010) Clin Rheumatol , vol.29 , pp. 1465-1467
    • Perdan-Pirkmajer, K.1    Praprotnik, S.2    Tomsic, M.3
  • 105
    • 84874848032 scopus 로고    scopus 로고
    • Case report: Successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease
    • [Epub ahead of print]
    • Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol. 2010; [Epub ahead of print].
    • (2010) Clin Rheumatol
    • Naniwa, T.1    Ito, R.2    Watanabe, M.3
  • 106
    • 79959933001 scopus 로고    scopus 로고
    • Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis
    • Kishida D, Okuda Y, Ohnishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011; 21: 215-218.
    • (2011) Mod Rheumatol , vol.21 , pp. 215-218
    • Kishida, D.1    Okuda, Y.2    Ohnishi, M.3
  • 107
    • 83555172604 scopus 로고    scopus 로고
    • Treatment of refractory adult-onset Still's disease with tocilizumab: Report of two cases and review of the literature
    • Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011; 31: 1653-1656.
    • (2011) Rheumatol Int , vol.31 , pp. 1653-1656
    • Thonhofer, R.1    Hiller, M.2    Just, H.3
  • 108
    • 78751701824 scopus 로고    scopus 로고
    • Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of interleu-kin-6 blockade and review of the literature
    • Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of interleu-kin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011; 40: 365-368.
    • (2011) Semin Arthritis Rheum , vol.40 , pp. 365-368
    • Sabnis, G.R.1    Gokhale, Y.A.2    Kulkarni, U.P.3
  • 109
    • 78751684939 scopus 로고    scopus 로고
    • Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade
    • Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade. Ann Rheum Dis. 2011; 70: 390-392.
    • (2011) Ann Rheum Dis , vol.70 , pp. 390-392
    • Rech, J.1    Ronneberger, M.2    Englbrecht, M.3
  • 110
    • 79951948588 scopus 로고    scopus 로고
    • Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome
    • Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011; 21: 92-96.
    • (2011) Mod Rheumatol , vol.21 , pp. 92-96
    • Kobayashi, M.1    Takahashi, Y.2    Yamashita, H.3
  • 111
    • 79952224572 scopus 로고    scopus 로고
    • Tocilizumab in refractory adult Still's disease
    • Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011; 63: 155-159.
    • (2011) Arthritis Care Res , vol.63 , pp. 155-159
    • Puechal, X.1    Debandt, M.2    Berthelot, J.M.3
  • 112
    • 79959790777 scopus 로고    scopus 로고
    • Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease
    • Sekkach Y, Elqatni M, Khattabi AE, et al. Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease. Presse Med. 2011; 40: e333-e337.
    • (2011) Presse Med , vol.40
    • Sekkach, Y.1    Elqatni, M.2    Khattabi, A.E.3
  • 113
    • 84871077056 scopus 로고    scopus 로고
    • Therapeutic response of patients with adult Still's disease to biologic agents: Multicenter results in Japan
    • [Epub ahead of print]
    • Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2011; [Epub ahead of print].
    • (2011) Mod Rheumatol
    • Suematsu, R.1    Ohta, A.2    Matsuura, E.3
  • 114
    • 33749331603 scopus 로고    scopus 로고
    • Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis
    • Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54: 2997-3000.
    • (2006) Arthritis Rheum , vol.54 , pp. 2997-3000
    • Okuda, Y.1    Takasugi, K.2
  • 115
    • 67549125131 scopus 로고    scopus 로고
    • Rapid improvement of AA amy-loidosis with humanised anti-interleukin 6 receptor antibody treatment
    • Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amy-loidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009; 68: 1235-1236.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1235-1236
    • Nishida, S.1    Hagihara, K.2    Shima, Y.3
  • 116
    • 70350435731 scopus 로고    scopus 로고
    • Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis
    • Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009; 28: 1113-1116.
    • (2009) Clin Rheumatol , vol.28 , pp. 1113-1116
    • Sato, H.1    Sakai, T.2    Sugaya, T.3
  • 117
    • 79952110725 scopus 로고    scopus 로고
    • Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis
    • Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010; 29: 1195-1197.
    • (2010) Clin Rheumatol , vol.29 , pp. 1195-1197
    • Inoue, D.1    Arima, H.2    Kawanami, C.3
  • 118
    • 79958084061 scopus 로고    scopus 로고
    • Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis
    • De La Torre M, Arboleya L, Pozo S, et al. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus. 2011; 4: 178-180.
    • (2011) NDT Plus , vol.4 , pp. 178-180
    • De La Torre, M.1    Arboleya, L.2    Pozo, S.3
  • 119
    • 81255201300 scopus 로고    scopus 로고
    • Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis
    • Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis. Amyloid. 2011; 18: 235-239.
    • (2011) Amyloid , vol.18 , pp. 235-239
    • Magro-Checa, C.1    Navas-Parejo Casado, A.2    Borrego-Garcia, E.3
  • 120
    • 84857220265 scopus 로고    scopus 로고
    • Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis
    • Hattori Y, Ubara Y, Sumida K, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012; 19: 37-40.
    • (2012) Amyloid , vol.19 , pp. 37-40
    • Hattori, Y.1    Ubara, Y.2    Sumida, K.3
  • 121
    • 77951783966 scopus 로고    scopus 로고
    • Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica
    • Hagihara K, Kawase I, Tanaka T, et al. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010; 37: 1075-1076.
    • (2010) J Rheumatol , vol.37 , pp. 1075-1076
    • Hagihara, K.1    Kawase, I.2    Tanaka, T.3
  • 122
    • 77951729315 scopus 로고    scopus 로고
    • Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab
    • Tanaka T, Hagihara K, Shima Y, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford). 2010; 49: 824-826.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 824-826
    • Tanaka, T.1    Hagihara, K.2    Shima, Y.3
  • 123
    • 84861483650 scopus 로고    scopus 로고
    • A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
    • Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012; 22: 298-302.
    • (2012) Mod Rheumatol , vol.22 , pp. 298-302
    • Hirano, T.1    Ohguro, N.2    Hohki, S.3
  • 124
    • 84857783564 scopus 로고    scopus 로고
    • Tocilizumab treatment for neu-ro-Behcet's disease, the first report
    • Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neu-ro-Behcet's disease, the first report. Clin Neurol Neurosurgery. 2011; 114: 297-298.
    • (2011) Clin Neurol Neurosurgery , vol.114 , pp. 297-298
    • Shapiro, L.S.1    Farrell, J.2    Haghighi, A.B.3
  • 125
    • 80053632353 scopus 로고    scopus 로고
    • Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis
    • Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunol In-flamm. 2011; 19: 382-383.
    • (2011) Ocular Immunol In-flamm , vol.19 , pp. 382-383
    • Muselier, A.1    Bielefeld, P.2    Bidot, S.3
  • 126
    • 78049508308 scopus 로고    scopus 로고
    • Effectiveness and safety of tocili-zumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease
    • Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocili-zumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Onocol. 2010; 28: e602-e604.
    • (2010) J Clin Onocol , vol.28
    • Gergis, U.1    Arnason, J.2    Yantiss, R.3
  • 127
    • 81255163590 scopus 로고    scopus 로고
    • Tocilizumab for the treatment of steroid refractory graft versus host disease
    • Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant. 2011; 17: 1862-1868.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 1862-1868
    • Drobyski, W.R.1    Pasquini, M.2    Kovatovic, K.3
  • 128
    • 79953689919 scopus 로고    scopus 로고
    • Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab
    • Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011; 63: 1151-1155.
    • (2011) Arthritis Rheum , vol.63 , pp. 1151-1155
    • Vaitla, P.M.1    Radford, P.M.2    Tighe, P.J.3
  • 129
    • 73449141147 scopus 로고    scopus 로고
    • Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocili-zumab
    • Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocili-zumab. Arthritis Rheum. 2009; 61: 1762-1764.
    • (2009) Arthritis Rheum , vol.61 , pp. 1762-1764
    • Tanaka, T.1    Kuwahara, Y.2    Shima, Y.3
  • 130
    • 78049418460 scopus 로고    scopus 로고
    • Mixed response to tocilizumab for ankylosing spondylitis
    • Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010; 69: 2217-2218.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2217-2218
    • Henes, J.C.1    Horger, M.2    Guenaydin, I.3
  • 131
    • 78649904087 scopus 로고    scopus 로고
    • Short-term effect of IL-6 inhibition in spondylarthritis
    • Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine. 2010; 77: 624-625.
    • (2010) Joint Bone Spine , vol.77 , pp. 624-625
    • Wendling, D.1    Bossert, M.2    Prati, C.3
  • 132
    • 78649907237 scopus 로고    scopus 로고
    • Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists
    • Brulhart L, Nissen MJ, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010; 77: 625-626.
    • (2010) Joint Bone Spine , vol.77 , pp. 625-626
    • Brulhart, L.1    Nissen, M.J.2    Chevallier, P.3
  • 133
    • 83255164666 scopus 로고    scopus 로고
    • Tocilizumab, a humanized an-ti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis
    • Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized an-ti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol. 2011; 21: 436-439.
    • (2011) Mod Rheumatol , vol.21 , pp. 436-439
    • Shima, Y.1    Tomita, T.2    Ishii, T.3
  • 134
    • 79959965088 scopus 로고    scopus 로고
    • Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab
    • Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol. 2011; 38: 1527.
    • (2011) J Rheumatol , vol.38 , pp. 1527
    • Cohen, J.D.1    Ferreira, R.2    Jorgensen, C.3
  • 135
    • 84860767082 scopus 로고    scopus 로고
    • Interleukin 6 blockade in spon-dyloarthritis
    • Koumakis E, Feydy A, Kahan A, et al. Interleukin 6 blockade in spon-dyloarthritis. J Rheumatol. 2012; 39: 1097-1098.
    • (2012) J Rheumatol , vol.39 , pp. 1097-1098
    • Koumakis, E.1    Feydy, A.2    Kahan, A.3
  • 136
    • 84855674874 scopus 로고    scopus 로고
    • Tocilizumab in axial spondylarthropathies: About 18 cases
    • Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthropathies: about 18 cases. Ann Rheum Dis. 2010; 70: 128.
    • (2010) Ann Rheum Dis , vol.70 , pp. 128
    • Dudler, J.1    Aubry-Rozier, B.2
  • 137
    • 84855672444 scopus 로고    scopus 로고
    • Tocilizumab for treatment of refractory spondyarthritis: Report of 5 patients
    • Del Castillo Pinol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyarthritis: report of 5 patients. Ann Rheum Dis. 2011; 70: 343.
    • (2011) Ann Rheum Dis , vol.70 , pp. 343
    • Del Castillo Pinol, N.1    Gossec, L.2    Sparsa, L.3
  • 138
    • 84855716888 scopus 로고    scopus 로고
    • Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab
    • Ogata A, Umegaki N, Katayama I, et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 2012; 79: 85-87.
    • (2012) Joint Bone Spine , vol.79 , pp. 85-87
    • Ogata, A.1    Umegaki, N.2    Katayama, I.3
  • 139
    • 70350571214 scopus 로고    scopus 로고
    • Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease
    • Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol. 2009; 90: 99-102.
    • (2009) Int J Hematol , vol.90 , pp. 99-102
    • Taniguchi, K.1    Shimazaki, C.2    Fujimoto, Y.3
  • 140
    • 77956051502 scopus 로고    scopus 로고
    • The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease
    • Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels. 2010; 25: 444-447.
    • (2010) Heart Vessels , vol.25 , pp. 444-447
    • Arita, Y.1    Sakata, Y.2    Sudo, T.3
  • 141
    • 79955116824 scopus 로고    scopus 로고
    • Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension
    • Article ID 720305
    • Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol. 2010; Article ID 720305
    • (2010) Int J Rheumatol
    • Furuya, Y.1    Satoh, T.2    Kuwana, M.3
  • 142
    • 80055076585 scopus 로고    scopus 로고
    • Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial su-perinfection
    • Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial su-perinfection. J Allergy Clin Immunol. 2011; 128: 1128-1130.
    • (2011) J Allergy Clin Immunol , vol.128 , pp. 1128-1130
    • Navarini, A.A.1    French, L.E.2    Hofbauer, G.F.L.3
  • 143
    • 84868142444 scopus 로고    scopus 로고
    • Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica
    • [Epub ahead of print]
    • Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012; [Epub ahead of print].
    • (2012) Eur Spine J
    • Ohtori, S.1    Miyagi, M.2    Eguchi, Y.3
  • 144
    • 79955807238 scopus 로고    scopus 로고
    • Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocili-zumab
    • Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocili-zumab. Ann Rheum Dis. 2011; 70: 1164-1165.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1164-1165
    • Ogata, A.1    Morishima, A.2    Hirano, T.3
  • 145
    • 78650781728 scopus 로고    scopus 로고
    • Effects of inhibition of interleu-kin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases
    • Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleu-kin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010; 5: e14328.
    • (2010) PLoS One , vol.5
    • Schultz, O.1    Oberhauser, F.2    Saech, J.3
  • 146
    • 84872272661 scopus 로고    scopus 로고
    • Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
    • [Epub ahead of print]
    • Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int. 2011; [Epub ahead of print].
    • (2011) Rheumatol Int
    • Hirao, M.1    Yamasaki, N.2    Oze, H.3
  • 147
    • 84859218984 scopus 로고    scopus 로고
    • The interleukin-6 pathway and atherosclerosis
    • Matthijs Boekholdt S, Stores ESG. The interleukin-6 pathway and atherosclerosis. Lancet. 2012, 379: 1176-1178.
    • (2012) Lancet , vol.379 , pp. 1176-1178
    • Matthijs Boekholdt, S.1    Stores, E.S.G.2
  • 148
    • 84859210770 scopus 로고    scopus 로고
    • Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies
    • IL-6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al
    • IL-6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379: 1205-1213.
    • (2012) Lancet , vol.379 , pp. 1205-1213
  • 149
    • 84859215358 scopus 로고    scopus 로고
    • The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis
    • The Interleukin-6 Receptor Mendelian Randomization Analysis (IL-6R MR) Consortium, Hingorani AD, Casas JP
    • The Interleukin-6 Receptor Mendelian Randomization Analysis (IL-6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012; 379: 1214-1224.
    • (2012) Lancet , vol.379 , pp. 1214-1224
  • 150
    • 84857411475 scopus 로고    scopus 로고
    • Hitting a complex target: An update on inter-leukin-6 trans-signaling
    • Waetzig GH, Rose-John S. Hitting a complex target: an update on inter-leukin-6 trans-signaling. Expert Opin Ther Targets. 2012; 16: 225-236.
    • (2012) Expert Opin Ther Targets , vol.16 , pp. 225-236
    • Waetzig, G.H.1    Rose-John, S.2
  • 152
    • 78149324897 scopus 로고    scopus 로고
    • Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Cas-tleman disease
    • Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Cas-tleman disease. Blood. 2010; 116: 3627-3634.
    • (2010) Blood , vol.116 , pp. 3627-3634
    • Song, S.N.1    Tomosugi, N.2    Kawabata, H.3
  • 153
    • 84871059465 scopus 로고    scopus 로고
    • Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients
    • [Epub ahead of print]
    • Samson M, Audia S, Janikashvili N, et al. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum. 2012; [Epub ahead of print].
    • (2012) Arthritis Rheum
    • Samson, M.1    Audia, S.2    Janikashvili, N.3
  • 154
    • 79955569760 scopus 로고    scopus 로고
    • In vivo effects of the an-ti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment
    • Roll P, Muhammad K, Schumann M, et al. In vivo effects of the an-ti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011; 63: 1255-1264.
    • (2011) Arthritis Rheum , vol.63 , pp. 1255-1264
    • Roll, P.1    Muhammad, K.2    Schumann, M.3
  • 155
    • 79959807954 scopus 로고    scopus 로고
    • Impact of IL-6 receptor inhibition on human memory B cells in vivo: Impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cells
    • Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cells. Ann Rheum Dis. 2011; 70: 1507-1510.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1507-1510
    • Muhammad, K.1    Roll, P.2    Seibold, T.3
  • 156
    • 79952762854 scopus 로고    scopus 로고
    • Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neu-romyelitis optica
    • Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neu-romyelitis optica. Proc Natl Acad Sci USA. 2011; 108: 3701-3706.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 3701-3706
    • Chihara, N.1    Aranami, T.2    Sato, W.3
  • 157
    • 0026611673 scopus 로고
    • IL-6 and NF-IL6 in acute-phase response and viral infection
    • Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 1992; 127: 25-50.
    • (1992) Immunol Rev , vol.127 , pp. 25-50
    • Akira, S.1    Kishimoto, T.2
  • 158
    • 0027453552 scopus 로고
    • Transcriptional factor NF-IL-6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8
    • Matsusaka T, Fujikawa K, Nishio Y, et al. Transcriptional factor NF-IL-6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA. 1993; 90: 10193-10197.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 10193-10197
    • Matsusaka, T.1    Fujikawa, K.2    Nishio, Y.3
  • 159
    • 38349114778 scopus 로고    scopus 로고
    • P38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements
    • Zhao W, Liu M, Kirkwood KL. P38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 2008; 283: 1778-1785.
    • (2008) J Biol Chem , vol.283 , pp. 1778-1785
    • Zhao, W.1    Liu, M.2    Kirkwood, K.L.3
  • 160
    • 81255154489 scopus 로고    scopus 로고
    • The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1
    • Iwasaki H, Takeuchi O, Teraguchi S, et al. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol. 2011; 12: 1167-1175.
    • (2011) Nat Immunol , vol.12 , pp. 1167-1175
    • Iwasaki, H.1    Takeuchi, O.2    Teraguchi, S.3
  • 161
    • 79952386909 scopus 로고    scopus 로고
    • Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression
    • Kang JG, Pripuzova N, Majerciak V, et al. Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol. 2011; 85: 2620-2630.
    • (2011) J Virol , vol.85 , pp. 2620-2630
    • Kang, J.G.1    Pripuzova, N.2    Majerciak, V.3
  • 162
    • 74949116731 scopus 로고    scopus 로고
    • Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes
    • Qin Z, Keamey P, Plaisance K, et al. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leu-koc Biol. 2010; 87: 25-34.
    • (2010) J Leu-koc Biol , vol.87 , pp. 25-34
    • Qin, Z.1    Keamey, P.2    Plaisance, K.3
  • 163
    • 0023900857 scopus 로고
    • HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor
    • Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature. 1988; 333: 776-778.
    • (1988) Nature , vol.333 , pp. 776-778
    • Leung, K.1    Nabel, G.J.2
  • 164
    • 0023712373 scopus 로고
    • HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene
    • Ballard DW, Bohnlein E, Lowenthal JW, et al. HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988; 241: 1652-1655.
    • (1988) Science , vol.241 , pp. 1652-1655
    • Ballard, D.W.1    Bohnlein, E.2    Lowenthal, J.W.3
  • 165
    • 0027955428 scopus 로고
    • The expression of the interleu-kin 6 gene is induced by the human immunodeficiency virus 1 TAT protein
    • Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleu-kin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med. 1994; 179: 961-971.
    • (1994) J Exp Med , vol.179 , pp. 961-971
    • Scala, G.1    Ruocco, M.R.2    Ambrosino, C.3
  • 166
    • 0030914237 scopus 로고    scopus 로고
    • HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors
    • Ambrosino C, Ruocco MR, Chen X, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem. 1997; 272: 14883-14892.
    • (1997) J Biol Chem , vol.272 , pp. 14883-14892
    • Ambrosino, C.1    Ruocco, M.R.2    Chen, X.3
  • 167
    • 0025768552 scopus 로고
    • Hepatitis B virus X protein transac-tivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT /enhancer-binding protein-like cis-elements
    • Mahe Y, Mukaida N, Kuno K, et al. Hepatitis B virus X protein transac-tivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT /enhancer-binding protein-like cis-elements. J Biol Chem. 1991; 266: 13759-13763.
    • (1991) J Biol Chem , vol.266 , pp. 13759-13763
    • Mahe, Y.1    Mukaida, N.2    Kuno, K.3
  • 168
    • 0032959637 scopus 로고    scopus 로고
    • Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain
    • Ohno H, Kaneko S, Lin Y, et al. Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol. 1999; 58: 11-18.
    • (1999) J Med Virol , vol.58 , pp. 11-18
    • Ohno, H.1    Kaneko, S.2    Lin, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.